site stats

Elaprase monograph

WebELAPRASE ® (Idursulfase) is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking … WebELAPRASE is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has …

Elaprase (IV Infusion): Uses, Dosage, Side Effects - Drugs.com

WebELAPRASE is a prescription medicine for patients with Hunter syndrome. ELAPRASE has been shown to improve walking ability in patients 5 yrs and older. In patients 16 months to 5 years old, ELAPRASE did not show improvement in disease-related symptoms or long-term clinical results; however, treatment with ELAPRASE has reduced spleen size ... WebElaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials. 4.2 Posology and method of administration This treatment should be supervised by a physician or other healthcare professional experienced in the svica zemljevid https://rooftecservices.com

Elaprase Dosage Guide - Drugs.com

WebIndications and Usage. ELAPRASE ® (Idursulfase) is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term ... WebDrug Names # A B C D E F G H WebEach vial of Elaprase is intended for single use only and contains 6 mg of idursulfase in 3 ml of solution. Elaprase is for intravenous infusion and must be diluted in sodium chloride 9 mg/ml (0.9%) solution for infusion prior to use. It is recommended to deliver the total volume of infusion using a 0.2 µm in line filter. basal texture

Elaprase Entire Monograph - Epocrates Web

Category:Elaprase (idursulfase) dosing, indications, interactions, adverse ...

Tags:Elaprase monograph

Elaprase monograph

Elaprase Dosage Guide - Drugs.com

WebMonographie MDd’ELAPRASE Page 1 de 34. MONOGRAPHIE DE PRODUIT . INCLUANT LES RENSEIGNEMENTS SUR LE MÉDICAMENT POUR LE PATIENT . Pr ELAPRASEMD. idursulfase pour injec tion . Formule concentrée de 2 mg/mL à diluer en solution pour perfusion intraveineuse . Enzymothérapie de remplacement . WebELAPRASE is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has …

Elaprase monograph

Did you know?

WebPediatric drug monographs for elaprase provide an overview of the product, therapeutic uses, key development issues, regulatory information on ScriptSave WellRx. WebJul 24, 2006 · Drug Review Package. 10903 New Hampshire Avenue Silver Spring, MD 20993 Ph. 1-888-INFO-FDA (1-888-463-6332) Contact FDA

WebAug 10, 2024 · Participants will be treated with ELAPRASE for up to 104 weeks. The prophylactic ITR will start 1 day prior to the start of ELAPRASE. The prophylactic ITR will consist of a 5-week cycle of: Rituximab (intravenously [IV], weekly for 4 weeks); Methotrexate (oral, 3 times per week for 5 weeks) and intravenous immunoglobulin … WebELAPRASE is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line. In conjunction with the market approval of ELAPRASE, Shire Human Genetic Therapies (the Shire business unit focused on genetic diseases) has introduced a new product support center called …

WebDec 19, 2024 · ELAPRASE is an intravenous enzyme replacement therapy approved for the treatment of patients with Hunter syndrome in 70+ countries worldwide including countries in Africa, Asia Pacific, Europe, Latin America and North America. 1. In the E.U., ELAPRASE is indicated for the long-term treatment of patients with Hunter syndrome. 2 WebBlack Box Warnings. Anaphylactoid reactions, which may be life threatening, have been observed in some patients during idursulfase infusions. Anaphylaxis, presenting as respiratory distress, hypoxia, hypotension, urticaria and/or angioedema of throat or tongue have been reported to occur during and after infusions, regardless of duration of the ...

WebElaprase (idursulfase) dosing, indications, interactions, adverse effects, and more Drugs & Diseases idursulfase (Rx) Brand and Other Names: Elaprase Classes: Enzymes, …

WebOct 21, 2024 · Prepare and use ELAPRASE according to the following steps using aseptic technique: Determine the total volume of ELAPRASE to be administered and the number of vials needed based on the patient's weight and the recommended dose of 0.5 mg/kg. Patient's weight (kg) × 0.5 mg per kg of ELAPRASE ÷ 2 mg per mL =. Total mL of … basaltfaserbandWebPediatric drug monographs for elaprase provide an overview of the drug product, therapeutic uses, key development issues, regulatory information, and therapeutic classifications on ScriptSave WellRx. basaltex meridaWebIndications and Usage ELAPRASE ® (Idursulfase) is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long … svi cdc/atsdrWebOct 1, 2024 · Prepare and use Elaprase according to the following steps using aseptic technique: Determine the total volume of Elaprase to be administered and the number of … svi ccnaWebDec 5, 2024 · DESCRIPTION. ELAPRASE is a formulation of idursulfase, a purified form of human iduronate-2-sulfatase, a lysosomal enzyme.Idursulfase is produced by recombinant DNA technology in a human cell line. Idursulfase is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan … basaltfaserWebELAPRASE is a prescription medicine for patients with Hunter syndrome. ELAPRASE has been shown to improve walking ability in patients 5 yrs and older. In patients 16 months to 5 yrs old, ELAPRASE did not show improvement in disease-related symptoms or long-term clinical result; however, treatment with ELAPRASE has reduced spleen size similarly ... svi cdc atsdrWebProduct Monograph. CUVITRU® Normal Immunoglobulin (Human) Product Monograph. DEXILANT ® dexlansoprazole. Product Monograph: ELAPRASE ® idursulfase for … basaltfiber